首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2039137

Pyrazinamide市場：按患者類型、分銷管道和地區分類

Pyrazinamide Market, By Patient Type (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，Pyrazinamide市場規模將達到 75.3 億美元，到 2033 年將達到 172.3 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 10.9%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	75.3億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	10.90%	預計金額（2033 年）	172.3億美元

Pyrazinamide(PZA) 是一種用於治療結核病的藥物。此外，在活動性結核病病例中，它通常與利福平、異煙肼以及鏈黴素或乙胺丁醇合併使用。一般來說，不建議用於治療潛伏性結核病。Pyrazinamide是所有用於治療藥物敏感性結核病和耐多藥結核病 (MDR-TB) 的聯合治療中必不可少的藥物，因為它能殺死其他抗結核藥物無法殺滅的非增殖性持續性細菌。Pyrazinamide的作用機制與其他抗生素不同，它透過抑制能量產生、翻譯和輔酶A來發揮作用，而這些對於持續性細菌的存活至關重要。藥物標靶基因突變的增加導致了對吡嗪醯胺抗藥性增強的菌株的出現。最近，在抗藥性菌株中發現了 panD 突變以及 pncA 和 rpsA 突變。

市場動態

結核病帶來的沉重負擔預計將推動市場成長。例如，根據世界衛生組織統計，2017年新增結核病病例中，87%發生在結核病高負擔的30個國家。在這30個國家中，有8個國家（印度、中國、印尼、菲律賓、巴基斯坦、奈及利亞、孟加拉和南非）的新增結核病病例佔總數的2/3。

全球結核病負擔日益加重，預計將推動Pyrazinamide市場成長。例如，根據美國疾病管制與預防中心（CDC）的數據，2017年全球整體有1,000萬人感染結核病，130萬人死於結核病相關疾病。

此外，根據世界衛生組織2018年發布的數據，全球整體結核病年度總成本高達210億美元，其中92億美元用於治療和預防，120億美元用於其他經濟損失和生產力損失。因此，結核病治療方面不斷成長的醫療保健支出預計將推動市場成長。

此外，據世界衛生組織稱，治療多重抗藥性結核病 (MDR-TB) 需要 20 至 26 個月，在美國治療的平均費用約為 294,000 美元。

此外，用於開發結核病新治療方法的研發投入增加，預計將抑制Pyrazinamide藥物市場的成長。例如，根據《2005-2017年結核病研究經費趨勢》報告，2017年全球結核病研究投資額為7.72億美元，較2016年的7.26億美元成長6%（4,600萬美元）。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本節根據各種參數（公司概況、財務表現、產品系列、企業發展區域、分銷策略、主要趨勢和策略等）對全球Pyrazinamide市場的主要公司進行介紹。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球Pyrazinamide市場》報告針對不孕症治療和醫療設備行業的眾多相關人員，包括投資者、經銷商、分銷商、供應商、研究和諮詢公司、新進業者和金融分析師。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 波灣合作理事會（GCC）國家
- 以色列
- 其他中東國家
非洲
- 南部非洲
- 北非
- 中非

第7章競爭情勢

Pure Chemistry Scientific
LGM Pharma
TCI
HBCChem
Alfa Chemistry
Toronto Research Chemicals
Acros Organics
AlliChem
Waterstone Technology
City Chemical
EDQM
J &K SCIENTIFIC
Meryer（Shanghai）Chemical Technology
Energy Chemical
Beijing Ouhe Technology

第8章分析師建議

機會
分析師意見
Coherent Opportunity Map (COM)

第9章參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI4317

Pyrazinamide Market is estimated to be valued at USD 7.53 Bn in 2026 and is expected to reach USD 17.23 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7.53 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.90%	2033 Value Projection:	USD 17.23 Bn

Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.

Market Dynamics

The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.

The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.

Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.

Key features of the study

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global pyrazinamide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts

Market Segmentation

By Patient Type (Revenue, USD Bn, 2021-2033)
- Adult
- Pediatric
By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Pyrazinamide Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Pure Chemistry Scientific
- LGM Pharma
- TCI
- HBCChem
- Alfa Chemistry
- Toronto Research Chemicals
- Acros Organics
- AlliChem
- Waterstone Technology
- City Chemical
- EDQM
- J & K SCIENTIFIC
- Meryer (Shanghai) Chemical Technology
- Energy Chemical
- Beijing Ouhe Technology

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Pyrazinamide Market, By Patient Type
- Global Pyrazinamide Market, By Distribution Channel
- Global Pyrazinamide Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Pyrazinamide Market, By Patient Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Pyrazinamide Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Pyrazinamide Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Pure Chemistry Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
LGM Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
TCI
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
HBCChem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alfa Chemistry
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Toronto Research Chemicals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Acros Organics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AlliChem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Waterstone Technology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
City Chemical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
EDQM
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
J & K SCIENTIFIC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Meryer (Shanghai) Chemical Technology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Energy Chemical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Beijing Ouhe Technology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies